Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

24,930 signal articles · 246 in last 24h · 118,817 total before filter · latest 25m ago
246last 24h
1549last 7d
262● bullish (7d)
159● bearish (7d)
205publishers
AllMacro295Earnings626M&A104Regulatory22Product14Analyst22
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
3 Reasons We’re Fans of ConocoPhillips (COP)
StockStory76d agoneutral
3 Reasons We’re Fans of ConocoPhillips (COP)

Over the past six months, ConocoPhillips has been a great trade, beating the S&P 500 by 17.1%. Its stock price has climbed to $117.57, representing a healthy 28.1% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

5-star analyst resets Oracle stock price target
TheStreet76d agoneutral
5-star analyst resets Oracle stock price target

Oracle (ORCL) stock closed the June 2 trading session down 1.44% at $244.58. Despite this slight drop, the stock is now up about 25.48% year to date, at the time of writing, Wednesday morning, June 3. Meanwhile, the SPDR S&P 500 Index (SPY) is up about 11.39% in the same period. Oracle has ...

Paychex (PAYX): Buy, Sell, or Hold Post Q1 Earnings?
StockStory76d agoneutral
Paychex (PAYX): Buy, Sell, or Hold Post Q1 Earnings?

Over the past six months, Paychex’s stock price fell to $100.59. Shareholders have lost 11.3% of their capital, which is disappointing considering the S&P 500 has climbed by 10.9%. This might have investors contemplating their next move.

After Comparing Every Covered Call S&P 500 ETF These 3 Pay Up to 12 Percent Without Touching Principal
24/7 Wall St.76d agoneutral
After Comparing Every Covered Call S&P 500 ETF These 3 Pay Up to 12 Percent Without Touching Principal

Covered call ETFs tied to the S&P 500 have become the default income vehicle for investors seeking monthly distributions without sacrificing large-cap equity exposure. Three funds dominate the conversation: JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), NEOS S&P 500 High Income ETF (NYSEARCA:SPYI), and Amplify CWP Enhanced Dividend Income ETF (NYSEARCA:DIVO). Each writes calls against US ... After Comparing Every Covered Call S&P 500 ETF These 3 Pay Up to 12 Percent Without Touching Princip

3 Reasons to Avoid COMP and 1 Stock to Buy Instead
StockStory76d agobullish
3 Reasons to Avoid COMP and 1 Stock to Buy Instead

Over the past six months, Compass’s shares (currently trading at $8.57) have posted a disappointing 18.4% loss, well below the S&P 500’s 10.9% gain. This may have investors wondering how to approach the situation.

3 Big Reasons to Love ITT (ITT)
StockStory76d agoneutral
3 Big Reasons to Love ITT (ITT)

ITT has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 7.5% to $194.15 per share while the index has gained 10.9%.

What a $1,000 Bet on IonQ Since Its SPAC Debut Is Worth Today
24/7 Wall St.76d agoneutral
What a $1,000 Bet on IonQ Since Its SPAC Debut Is Worth Today

From University Lab to Quantum Hype Stock IonQ (NYSE:IONQ) hit the public market in October 2021 via a SPAC merger with dMY Technology Group III, becoming the first pure-play quantum computing stock investors could actually buy. The pitch was bold: a trapped-ion architecture spun out of University of Maryland and Duke research, aimed at solving ... What a $1,000 Bet on IonQ Since Its SPAC Debut Is Worth Today

3 Reasons IIIN is Risky and 1 Stock to Buy Instead
StockStory76d agobullish
3 Reasons IIIN is Risky and 1 Stock to Buy Instead

Over the last six months, Insteel’s shares have sunk to $28.17, producing a disappointing 10.4% loss - a stark contrast to the S&P 500’s 10.9% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

2 Reasons to Like ALSN (and 1 Not So Much)
StockStory76d agoneutral
2 Reasons to Like ALSN (and 1 Not So Much)

Since June 2021, the S&P 500 has delivered a total return of 81.1%. But one standout stock has more than doubled the market - over the past five years, Allison Transmission has surged 180% to $118.17 per share. Its momentum hasn’t stopped as it’s also gained 30.5% in the last six months thanks to its solid quarterly results, beating the S&P by 19.6%.

3 Reasons to Sell BKU and 1 Stock to Buy Instead
StockStory76d agoneutral
3 Reasons to Sell BKU and 1 Stock to Buy Instead

Since December 2025, BankUnited has been in a holding pattern, posting a small return of 4.7% while floating around $46.68. The stock also fell short of the S&P 500’s 10.9% gain during that period.

CNBC Anchor Issues Dire Stock Market Warning: “I Can Assure You… We Will Have a Crash”
24/7 Wall St.76d agobearish
CNBC Anchor Issues Dire Stock Market Warning: “I Can Assure You… We Will Have a Crash”

The bears have been quiet in the last two years, even though the market is much more frothy by their standards. And at this point, who would want the permabear tag while the rest of the market keeps on climbing ad infinitum? Andrew Ross Sorkin seems to be the person. His arguments are worth lending ... CNBC Anchor Issues Dire Stock Market Warning: “I Can Assure You… We Will Have a Crash”

Mega-Cap Growth Leadership or Small-Cap Growth Potential? VUG vs. VBK
Motley Fool76d agoneutral
Mega-Cap Growth Leadership or Small-Cap Growth Potential? VUG vs. VBK

The Vanguard Growth ETF (VUG) is tied closely to the market’s largest growth companies, while the Vanguard Small-Cap Growth ETF (VBK) spreads exposure across smaller firms with less certain earnings paths. For investors seeking growth, the choice is really about whether to lean on today’s dominant leaders or look further down the market for the next wave of growth.

AbbVie Delivers 400% Returns Beating The S&P 500 by 139%
24/7 Wall St.76d agobullish
AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

1 Industrials Stock to Target This Week and 2 We Ignore
StockStory76d agoneutral
1 Industrials Stock to Target This Week and 2 We Ignore

Even if they go mostly unnoticed, industrial businesses are the backbone of our country. But their prominence also brings high exposure to the ups and downs of economic cycles. Luckily, the tide is turning in their favor as the industry’s 19.6% return over the past six months has topped the S&P 500 by 8.6 percentage points.

StockStory77d agoneutral
1 Energy Stock with Competitive Advantages and 2 We Find Risky

Energy businesses quietly power the physical things we depend on, from cars and homes to e-commerce infrastructure. They are also bound to benefit from a friendlier regulatory environment with the “American energy dominance” stance of the Trump administration, and this excitement has led to a six-month gain of 28.5% for the sector - higher than the S&P 500’s 10.9% return.